Kidney Transplantation in Multiple Myeloma: Patient Selection, Timing, and Post-Transplant Challenges in the Modern Therapeutic Era

Clicks: 12
ID: 329636
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #202 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
ABSTRACT Kidney involvement is a common and clinically significant complication of multiple myeloma (MM), with a subset of patients progressing to end-stage kidney disease (ESKD). Historically, kidney transplantation was considered contraindicated in MM due to poor prognosis and high relapse rates. However, the introduction of novel anti-myeloma therapies has markedly improved hematologic responses and patient survival, leading to reconsideration of transplantation in this population. This review summarizes current evidence on patient selection, optimal timing, and post-transplant management of kidney transplantation in MM. Candidate selection should be guided by disease biology, depth of hematologic response, and remission durability. Transplantation is preferentially considered in patients achieving at least very good partial response, ideally with minimal residual disease negativity, while timing should be individualized according to cytogenetic risk, remission duration, and overall disease stability. Post-transplant management requires balancing immunosuppression with the competing risks of relapse, infection, and graft rejection. The optimal role of maintenance therapy remains uncertain, particularly given the potential interaction between anti-myeloma agents and allograft immunity. Available evidence, derived mainly from retrospective studies and small cohorts, suggests that patient and graft outcomes in carefully selected MM patients may approach those observed in other causes of ESKD. Although important uncertainties remain, kidney transplantation should be considered a viable treatment option within a multidisciplinary framework. Future studies are needed to refine eligibility criteria, optimize timing, and define long-term management strategies in this evolving population.
Reference Key
openalex_W7214228980 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Amir Shabaka, Teresa De Soto, María O. López‐Oliva, Javier Azores‐Moreno, Carlos Jiménez-Martín
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag335
URL
https://doi.org/10.1093/ckj/sfag335
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.